chronic myeloid leukemia (CML) relapsed after allogeneic bone marrow transplantation (BMT). [1] [2] [3] [4] [5] Chimerism studies in patients who relapsed following an Recent observations of chimerism in patients relapsed following an allotransplant suggest the persistence of allotransplant suggest the persistence of immunotolerance thus offering a biologic rationale for the use of DLT. 6 Sevimmunotolerance, thus offering a biologic rationale for the use of donor lymphocyte transfusion (DLT). In this eral methods with different sensitivities are useful to evaluate the chimerism status in transplanted patients. These study, we have analyzed by PCR amplification of several VNTR regions, sequential bone marrow and peripheral include cytogenetics, Y body detection, protein polymorphism, and red cell phenotyping. 7-9 More recently, DNAblood DNA samples in four patients who received DLT for CML relapse after bone marrow transplantation.
Summary:
chronic myeloid leukemia (CML) relapsed after allogeneic bone marrow transplantation (BMT). [1] [2] [3] [4] [5] Chimerism studies in patients who relapsed following an Recent observations of chimerism in patients relapsed following an allotransplant suggest the persistence of allotransplant suggest the persistence of immunotolerance thus offering a biologic rationale for the use of DLT. 6 Sevimmunotolerance, thus offering a biologic rationale for the use of donor lymphocyte transfusion (DLT). In this eral methods with different sensitivities are useful to evaluate the chimerism status in transplanted patients. These study, we have analyzed by PCR amplification of several VNTR regions, sequential bone marrow and peripheral include cytogenetics, Y body detection, protein polymorphism, and red cell phenotyping. [7] [8] [9] More recently, DNAblood DNA samples in four patients who received DLT for CML relapse after bone marrow transplantation.
based methodology has provided more sensitive techniques.
In particular, polymerase chain reaction (PCR) amplifiPrior to DLT, all patients showed mixed chimerism in peripheral blood cells while two had mixed chimerism cation of individual specific genetic loci, such as the variable tandem repeats (VNTR) and the short tandem repeats and two no chimerism in the BM. None of these four patients showed evidence of chimerism at the cyto-(STR), have increased the sensitivity of the analysis up to 1-0.1% and 0.1-0.01%, respectively. 10,11 Using these genetic level (all had 100% +ve metaphases). After DLT, a complete hematologic and molecular remission (ie disassays, a condition of mixed chimerism (MC) has been shown in 80% of CML patients receiving T cell-depleted appearance of the BCR/ABL fusion transcript) was obtained in the two patients who had bone marrow allografts.
11
With regard to CML patients treated with DLT for mixed chimerism prior to DLT. The two patients without evidence of marrow chimerism prior to DLT conrelapse after BMT, Mackinnon et al 12 have analyzed the chimerism status of T lymphocytes by PCR and shown that verted to a pattern of mixed chimerism after DLT, but both developed a severe bone marrow aplasia occurring a MC was present in almost every patient prior to DLT. While this observation encourages the use of adoptive at day 56 and 36, respectively. With regard to the sequential analysis of bone marrow chimerism after immunotherapy in these patients, it provides no prognostic information on the post-DLT clinical outcome. DLT we observed that: (1) the disappearance of BCR/ABL +ve cells paralleled the conversion to a patIn this study, we have analyzed by PCR amplification of several VNTR regions sequential bone marrow and periphtern of full donor chimerism; and (2) the time interval to achieve CR was inversely correlated with the percenteral blood DNA samples in four patients who received DLT for CML relapse after BMT. We show that bone marrow age of donor DNA in bone marrow. In conclusion, we have shown here that the assessment of bone marrow chimerism pre-DLT is prognostically important, since it may predict either response to treatment or the occurrence pre-DLT chimerism by PCR analysis might predict the response in patients with favorable characteristics, and of severe aplasia. also might identify patients at high risk of developing severe myelosuppression. Keywords: chimerism; donor lymphocytes transfusion;
Materials and methods

CML relapse
Patients
Chimerism was evaluated in four patients (three males, one Donor lymphocyte transfusion (DLT) has been successfully female) with Ph +ve CML undergoing DLT for relapse employed as adoptive immunotherapy in patients with after an allogeneic HLA-identical BMT. The median age of the patients was 35 years (range 20-47). Marrow donors were sex mismatched in one case and ABO incompatible Prior to BMT all patients were conditioned by the associ-B and D4S95; 1 min at 94°C, 5 min at 65°C for the D1S80; 1 min at 94°C, 1 min at 55°C and 1 min at 72°C for the ation of 12 Gy fractionated total body irradiation (TBI) and cyclophosphamide combined with high-dose Ara-C in D17S30. An aliquot of each amplified reaction mixture was electrophoresed on a 8% polyacrylamide gel (acrylamide/ three cases.
For GVHD prophylaxis, all patients received a T cellbis-acrylamide ratio (37.5:1), and then stained with ethidium bromide and visualized under a UV lamp. In all cases, depleted graft and cyclosporine was added in three of them. No patient developed acute or chronic GVHD. The first the size of the PCR products was in the range expected for each VNTR locus.
15-18
evidence of relapse was cytogenetic in two patients (UPN 034, 036), with 7% and 50% of Ph +ve cells in the marrow, Negative controls consisting of all reagents plus water and no DNA were included in all experiments to detect and hematologic (one CP, and one accelerated phase (AP)) in the other two (UPN 007, 044). Interferon, alone or com-DNA contaminations. bined with hydroxyurea was used to treat patients with cytogenetic or hematologic relapse, respectively.
PCR detection of BCR/ABL fusion transcript
The interval between the first evidence of relapse and DLT was 92 (UPN 034), 93 (UPN 036), 14 (UPN 044) and RNA prepared from BM cells after stratification on a Ficoll-Hypaque density gradient, was extracted by the acid 108 (UPN 007) months. At the time of DLT, all patients showed 100% of Ph +ve cells in the marrow. Two cases guanidium/phenol-chloroform method. 19 To prepare cDNA, between 2 and 5 g of total RNA was added to a total received DLT for cytogenetic relapse and two for hematological relapse (one in CP and one in AP).
volume of 20 l reverse transcriptase reaction containing 1 × reverse transcriptase buffer (50 mm Tris-HCl pH 8.3, 75 mm KCl, 3 mm MgCl 2 ), 10 mm dithiotreitol (DTT), Donor lymphocyte transfusion 1 mm each dNTPs, RNase inhibitor 1 U/l, murine leukemia virus reverse transcriptase 2.5 U/l (Perkin-Elmer Peripheral blood mononuclear cells were collected from the donor by two or three leukaphereses using the Cobe Spectra Cetus) and 100 pmols of the following primer: 5′-TGTGATTATAGCCTAAGACCCGGAG-3′. Reactions Apheresis System (Lakewood, CO, USA). Collections were performed over 2 or 3 consecutive days. The number of were incubated at 42°C for 20 min, followed by 5 min at 99°C and 5 min at 4°C to inactivate the reverse trantransfused mononuclear cells ranged from 2.0 to 3.01 × 10 8 per kg of recipient body weight.
scriptase. To amplify the specific p210 BCR/ABL chimeric transcript, a nested PCR technique was used as previously described. 20 The amplified product was analyzed on ethidMolecular analysis of chimerism status ium-bromide 2% agarose gel and visualized under UV light. Negative and positive controls were performed to Cell nuclei were prepared from whole BM and PB by a Triton-X-100 based method.
13 High molecular weight DNA check each step of the RNA extraction and cDNA amplification. was extracted according to the salting-out method described by Miller et al.
14 To assess the chimerism status we amplified by PCR the following VNTR regions: (1) D1S80 (defined by the probe pMCT118); 15 (2) D4S95 (defined by Results the probe BS674E-D); 16 (3) apolipoprotein B locus (located on chromosome 2 in the 3′ hypervariable region); 17 and To test polymorphic variations in BM and PB DNA samples of the four donor-recipient pairs we used four (4) the D17S30 (defined by the probe pYNZ22). 18 The nucleotide sequences of the primers used are the following: minisatellite markers. Of these, the VNTR D1S80 was informative in patients UPN 007, 034 and 036, while the D1S80: 5′-GAAACTGGCCTCCAAACACTGCCCGCCG-3′ and 5′-GTCTTGTTGGAGATGCACGTGCCCCTTGCApo B was informative in patients UPN 044 and UPN 036. Serial dilution experiments performed by mixing known 3′; D4S95: 5′-GCATAAAATGGGGATAACAGTAC-3′ and 5′-GACATTGCTTTATAGCTGTGCCTCAGTTT-3′; amounts of host and donor DNA demonstrated that PCR amplification of D1S80 and Apo B VNTR regions allows ApoB 5′-AAACGGAGAAATTATGGAGGGA-3′ and 5′-CCTGAGATCAATAACCTCGT-3′; YNZ22 5′-CGAAthe detection of 0.5% individual specific DNA (Figure 1 ). Table 1 shows the chimeric status prior to DLT accord-GAGTGAAGTGCACAGG-3′ and 5′-CACAGTCTTTA-TTCTTCAGCG-3′. The minimum amount of genomic ing to BM karyotype, and DNA analysis of either BM or PB. None showed evidence of chimerism at cytogenetic DNA amplified was 200 ng for Apo B and D17S30 VNTR loci, 350 ng for D4S95 and 700 ng for D1S80.
analysis (all had 100% Ph +ve metaphases). With regard to DNA studies, all patients showed a MC in PB, while two PCR tests were performed in a final volume of 100 l containing 1 × PCR-gelatin buffer (50 mm KCl, 10 mm (UPN 036 and 044) had MC and two (UPN 007 and 034) had no chimerism in the BM. Tris-HCl pH 8.4, 1.5 mm MgCl 2 , and 200 g/ml gelatin). For each reaction we used 30 pmols of each primer, 200 m Table 2 shows the response to treatment, therapy-related complications and clinical and biological follow-up accorddNTPs, 0.2 U AmpliTaq (Thermus aquaticus DNA polymerase; Perkin-Elmer Cetus, Norwalk, CT, USA). For each ing to chimerism status. All patients developed acute grade I-II GVHD while VNTR region 30 cycles of DNA amplification were performed using a thermal cycler Perkin-Elmer 9600 (Perkinthree of them had chronic GVHD. A complete hematologic and molecular remission (ie disappearance of the Elmer Cetus), according to the following cycling parameters: 1 min at 94°C, 2 min at 60°C for the VNTR Apo BCR/ABL fusion transcript) was obtained in UPN 036 and 705 sion together with the disappearance of BCR/ABL fusion transcript and the conversion to a complete full donor chimerism (Figure 3a) , which persists at the last follow-up control (day 365 post-DLT). Moreover, in the responders the achievement of a molecular remission corresponded to the conversion to a pattern of full donor chimerism. Owing to donor refusal, PBSC reinfusion was not possible in case UPN 007 who died in aplasia at day 90 after DLT. Using a non-radioactive PCR-based approach to amplify patient and donor VNTR, we identified informative DNA polymorphisms which were also evaluated during the fol-044 who had shown a marrow MC prior to DLT. As illustrated in Figure 2 , the disappearance of BCR/ABL fusion low-up, in conjunction with the specific leukemia marker (ie BCR/ABL fusion transcript). transcript was more rapid (30 days post-DLT) in case UPN 044 than in case UPN 036 (425 days post-DLT). In these As demonstrated in serial dilution experiments, the amplification of these VNTR sequences identified up to two patients, the amount of BM pre-DLT donor DNA, estimated comparing the intensity of patient BM pre-DLT PCR 0.5-1% of individual specific DNA, thereby showing a sensitivity level comparable to that reported by using other products with those achieved amplifying pre-fixed known amounts of 'in vitro' mixed donor/host DNA (example in methods including radioactive and silver-staining detection systems. 10,11 Furthermore, our analysis allows us to detect Figure 1 ), was 70% and 5%, respectively. Patients UPN 007 and 034 who had no evidence of MC prior to DLT differences between PB and BM samples. In fact, mixed chimerism was detected in PB of all four patients and in converted to a pattern of MC after DLT, but both developed a severe BM aplasia at day 56 and 36, respectively BM of two of the four patients. This implies that in the two patients in whom no BM chimerism was detected, the ( Figure 3) .
Case UPN 034 was reinfused at day 60 after DLT with small amount of donor PB cells contaminating the marrow is diluted below the level of detectability according to the donor peripheral blood stem cells (PBSC) mobilized by G-CSF, achieving a prompt resolution of the myelosuppressensitivity of our test. and primers for the Apo B VNTR in case UPN 044. In this latter patient Figure 3 Sequential analysis of chimerism and BCR/ABL fusion tranpre-transplant host DNA was not available. However, mixed chimerism script in patients UPN 034 (a) and UPN 007 (b). Chimerism analysis was (ie three allelic pattern) was demonstrated both at relapse and prior to DLT performed on donor, host, and post-DLT sequential DNA samples using (lanes 2 and 3 b) . The analysis of BCR/ABL fusion transcript performed at for PCR amplification the primers for the D1S80 VNTR. In (a) the arrow the same time intervals from DLT is shown below.
indicates the time in which donor PBSCs were transfused to patients UPN 034 (see text). The parallel study of BCR/ABL fusion transcript done in patients' BM cells at the same time intervals from DLT is shown below
Recent clinical trials have reported that CML patients the chimerism analysis.
relapsed after BMT can be reinduced into hematologic and molecular CR by DLT, with relatively low toxicity. [1] [2] [3] [4] [5] Chimerism status has been recently investigated in CML Two studies have reported the assessment of pre-DLT BM chimerism in CML patients relapsed after BMT. Using patients receiving allogeneic BMT. 6, 10, 11, [21] [22] [23] Using PCRbased methods, Mackinnon et al 12 have reported the longSouthern blot RFLP analysis, erythrocyte phenotype and cytogenetics, these studies did not report correlations term persistence of donor memory T cells in all relapsed patients. While offering a biologic rationale for the use of between chimerism, response to DLT therapy and severe myelosuppression. 2, 4 We believe that such discordant DLT, this observation provides no prognostic information with regard to the clinical outcome. The result of our study results could be related to the inferior sensitivity of these techniques compared to PCR DNA analysis. 10, 22 In our suggests that assessment of chimerism in the BM appears to provide some clinically relevant information. In fact, perexperience, a condition of MC could be detected by PCR analysis in two patients who had shown absence of chimersistence of PCR detectable donor cells in BM prior to DLT was associated with hematologic and molecular remission ism by cytogenetics. BM aplasia is a major DLT-related complication which without risk of severe aplasia, whereas the absence of BM chimerism correlated with the occurrence of severe myelomay occur in up to 50% of patients. These patients can be successfully rescued with donor BM or PBSC reinfusuppression. 
